Israel's MediWound signs $112 million deal in U.S. for burn treatment

September 30, 2015 10:10 AM

13 0

JERUSALEM Israel-based MediWound has signed a five-year, $112 million contract with the U.S. authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.

Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.

Also read: EFG International says to cut up to 450 jobs in BSI integration

Read more

To category page

Loading...